Cargando…
Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study
BACKGROUND: In the emergency setting, non-traumatic headache is a benign symptom in 80% of cases, but serious underlying conditions need to be ruled out. Copeptin improves risk stratification in several acute diseases. Herein, we investigated the value of copeptin to discriminate between serious sec...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307398/ https://www.ncbi.nlm.nih.gov/pubmed/28197843 http://dx.doi.org/10.1186/s10194-017-0733-2 |
_version_ | 1782507366343770112 |
---|---|
author | Blum, Claudine Angela Winzeler, Bettina Nigro, Nicole Schuetz, Philipp Biethahn, Silke Kahles, Timo Mueller, Cornelia Timper, Katharina Haaf, Katharina Tepperberg, Janina Amort, Margareth Huber, Andreas Bingisser, Roland Sándor, Peter Stephan Nedeltchev, Krassen Müller, Beat Katan, Mira Christ-Crain, Mirjam |
author_facet | Blum, Claudine Angela Winzeler, Bettina Nigro, Nicole Schuetz, Philipp Biethahn, Silke Kahles, Timo Mueller, Cornelia Timper, Katharina Haaf, Katharina Tepperberg, Janina Amort, Margareth Huber, Andreas Bingisser, Roland Sándor, Peter Stephan Nedeltchev, Krassen Müller, Beat Katan, Mira Christ-Crain, Mirjam |
author_sort | Blum, Claudine Angela |
collection | PubMed |
description | BACKGROUND: In the emergency setting, non-traumatic headache is a benign symptom in 80% of cases, but serious underlying conditions need to be ruled out. Copeptin improves risk stratification in several acute diseases. Herein, we investigated the value of copeptin to discriminate between serious secondary headache and benign headache forms in the emergency setting. METHODS: Patients presenting with acute non-traumatic headache were prospectively enrolled into an observational cohort study. Copeptin was measured upon presentation to the emergency department. Primary endpoint was serious secondary headache defined by a neurologic cause requiring immediate treatment of the underlying disease. Secondary endpoint was the combination of mortality and hospitalization within 3 months. Two board-certified neurologist blinded to copeptin levels verified the endpoints after a structured 3-month-telephone interview. RESULTS: Of the 391 patients included, 75 (19%) had a serious secondary headache. Copeptin was associated with serious secondary headache (OR 2.03, 95%CI 1.52–2.70, p < 0.0001). Area under the curve (AUC) for copeptin to identify the primary endpoint was 0.70 (0.63–0.76). After adjusting for age > 50, focal-neurological abnormalities, and thunderclap onset of symptoms, copeptin remained an independent predictive factor for serious secondary headache (OR 1.74, 95%CI 1.26–2.39, p = 0.001). Moreover, copeptin improved the AUC of the multivariate logistic clinical model (p-LR-test < 0.001). Even though copeptin values were higher in patients reaching the secondary endpoint, this association was not significant in multivariate logistic regression. CONCLUSIONS: Copeptin was independently associated with serious secondary headache as compared to benign headaches forms. Copeptin may be a promising novel blood biomarker that should be further validated to rule out serious secondary headache in the emergency department. TRIAL REGISTRATION: Study Registration on 08/02/2010 as NCT01174901 at clinicaltrials.gov. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s10194-017-0733-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5307398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Milan |
record_format | MEDLINE/PubMed |
spelling | pubmed-53073982017-02-28 Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study Blum, Claudine Angela Winzeler, Bettina Nigro, Nicole Schuetz, Philipp Biethahn, Silke Kahles, Timo Mueller, Cornelia Timper, Katharina Haaf, Katharina Tepperberg, Janina Amort, Margareth Huber, Andreas Bingisser, Roland Sándor, Peter Stephan Nedeltchev, Krassen Müller, Beat Katan, Mira Christ-Crain, Mirjam J Headache Pain Research Article BACKGROUND: In the emergency setting, non-traumatic headache is a benign symptom in 80% of cases, but serious underlying conditions need to be ruled out. Copeptin improves risk stratification in several acute diseases. Herein, we investigated the value of copeptin to discriminate between serious secondary headache and benign headache forms in the emergency setting. METHODS: Patients presenting with acute non-traumatic headache were prospectively enrolled into an observational cohort study. Copeptin was measured upon presentation to the emergency department. Primary endpoint was serious secondary headache defined by a neurologic cause requiring immediate treatment of the underlying disease. Secondary endpoint was the combination of mortality and hospitalization within 3 months. Two board-certified neurologist blinded to copeptin levels verified the endpoints after a structured 3-month-telephone interview. RESULTS: Of the 391 patients included, 75 (19%) had a serious secondary headache. Copeptin was associated with serious secondary headache (OR 2.03, 95%CI 1.52–2.70, p < 0.0001). Area under the curve (AUC) for copeptin to identify the primary endpoint was 0.70 (0.63–0.76). After adjusting for age > 50, focal-neurological abnormalities, and thunderclap onset of symptoms, copeptin remained an independent predictive factor for serious secondary headache (OR 1.74, 95%CI 1.26–2.39, p = 0.001). Moreover, copeptin improved the AUC of the multivariate logistic clinical model (p-LR-test < 0.001). Even though copeptin values were higher in patients reaching the secondary endpoint, this association was not significant in multivariate logistic regression. CONCLUSIONS: Copeptin was independently associated with serious secondary headache as compared to benign headaches forms. Copeptin may be a promising novel blood biomarker that should be further validated to rule out serious secondary headache in the emergency department. TRIAL REGISTRATION: Study Registration on 08/02/2010 as NCT01174901 at clinicaltrials.gov. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s10194-017-0733-2) contains supplementary material, which is available to authorized users. Springer Milan 2017-02-13 /pmc/articles/PMC5307398/ /pubmed/28197843 http://dx.doi.org/10.1186/s10194-017-0733-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Article Blum, Claudine Angela Winzeler, Bettina Nigro, Nicole Schuetz, Philipp Biethahn, Silke Kahles, Timo Mueller, Cornelia Timper, Katharina Haaf, Katharina Tepperberg, Janina Amort, Margareth Huber, Andreas Bingisser, Roland Sándor, Peter Stephan Nedeltchev, Krassen Müller, Beat Katan, Mira Christ-Crain, Mirjam Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study |
title | Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study |
title_full | Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study |
title_fullStr | Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study |
title_full_unstemmed | Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study |
title_short | Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study |
title_sort | copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307398/ https://www.ncbi.nlm.nih.gov/pubmed/28197843 http://dx.doi.org/10.1186/s10194-017-0733-2 |
work_keys_str_mv | AT blumclaudineangela copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT winzelerbettina copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT nigronicole copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT schuetzphilipp copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT biethahnsilke copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT kahlestimo copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT muellercornelia copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT timperkatharina copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT haafkatharina copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT tepperbergjanina copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT amortmargareth copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT huberandreas copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT bingisserroland copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT sandorpeterstephan copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT nedeltchevkrassen copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT mullerbeat copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT katanmira copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy AT christcrainmirjam copeptinforriskstratificationinnontraumaticheadacheintheemergencysettingaprospectivemulticenterobservationalcohortstudy |